news-tldr.com

The important facts, the open questions, and the sources — without the churn.

← Latest briefing

Health

Roivant reports positive Phase 2 results for lung disease drug mosliciguat

Mosliciguat showed strong efficacy in a mid-stage trial for PH-ILD, according to STAT.

Updated Sep 10, 2026 · 10:47 UTC1 reports

The short version

  • Roivant's experimental therapy mosliciguat demonstrated strong efficacy in a Phase 2 trial for pulmonary hypertension associated with interstitial lung disease.[STAT]
  • The findings may offer an alternative therapeutic approach for patients with this serious respiratory condition.[STAT]
  • The drug could potentially serve as a second major blockbuster product to strengthen the company's finances.[STAT]

Key facts

  • Mosliciguat achieved strong efficacy in a Phase 2 clinical trial treating pulmonary hypertension associated with interstitial lung disease.[STAT]
  • The Phase 2 trial data may present a new treatment path for the serious lung condition.[STAT]

What remains uncertain

  • Whether mosliciguat will successfully achieve regulatory approval and become a second blockbuster medicine for Roivant remains unconfirmed.[STAT]

Sources

Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.